Stock Comparison

SKYE vs UNH

Skye Bioscience Inc vs UnitedHealth Group Inc

The Verdict

SKYE takes this one.

Winner

SKYE

Skye Bioscience Inc

5.5

out of 10

Proceed with Caution

UNH

UnitedHealth Group Inc

0.3

out of 10

Distressed

Head-to-Head

N/A

Market Cap

$276.2B

N/A

P/E Ratio

22.9

N/A

Profit Margin

2.7%

N/A

Return on Equity

12.5%

N/A

Debt-to-Equity

0.0

Aggressive

Overall Risk

Moderate-High

5.5

DVR Score

0.3

The Deep Dive

SKYE5.5/10

Skye Bioscience remains a highly speculative, high-risk/high-reward opportunity with potential for 10x growth, contingent on overcoming severe financial challenges. The company validated its novel cannabinoid-derived therapeutic approach with positive top-line Phase 2a data for SBI-100 (glaucoma) in November 2024, demonstrating significant clinical de-risking and a substantial TAM. However, this c...

Full SKYE Analysis

UNH0.3/10

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...

Full UNH Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.